In vivo biological evaluation of I-131 radiolabeled-paclitaxel glucuronide (I-131-PAC-G)


Aslan O., Muftuler F. Z. B. , Kilcar A. , Ichedef C. , Unak P.

RADIOCHIMICA ACTA, vol.100, no.5, pp.339-345, 2012 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 100 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1524/ract.2012.1922
  • Title of Journal : RADIOCHIMICA ACTA
  • Page Numbers: pp.339-345
  • Keywords: Paclitaxel (PAC), Paclitaxel-glucuronide, I-131-paclitaxel-glucuronide (I-131-PAC-G), BETA-D-GLUCURONIDE, RADIOIODINATION, PRODRUGS, BIODISTRIBUTION, DELIVERY, BIOAVAILABILITY, OPTIMIZATION, PEPTIDES, PROTEIN, CANCER

Abstract

Paclitaxel (PAC) is a natural occurring diterpene alkoloid originally isolated from the bark of Taxus Brevifolia. It is one of the most important antitumor agents for clinical treatment of ovarian, breast non-small cell lung and prostate cancers. It is known that these types of cancer cells have high beta-glucuronides enzyme which can catalyze the hydrolysis of glucuronides. This is why the synthesis compounds which undergo glucuronidation come into question in the imaging and therapy of these cancer cells.